Nektar Therapeutics (FRA:ITH0) Other Operating Expense: €-0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ITH0 Nektar Therapeutics FRA:ITH0
47 GF Score
Price €58.54
GF Value €5.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Other Operating Expense?

Nektar Therapeutics FRA:ITH0 +1.42% 47 Other Operating Expense is €-0.00 Mil as of Mar. 2026. GuruFocus rates FRA:ITH0 with a GF Score™ of 47/100 and a GF Value™ of €5.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Nektar Therapeutics's Other Operating Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00 Mil.

Nektar Therapeutics's quarterly Other Operating Expense increased from Sep. 2025 (€-0.00 Mil) to Dec. 2025 (€0.00 Mil) but then declined from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

Nektar Therapeutics's annual Other Operating Expense increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Nektar Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Other Operating Expense Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 -0.00

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00
FRA:ITH0
47GF Score
Nektar Therapeutics FRA:ITH0
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €-0.00 Mil mean?
Nektar Therapeutics (FRA:ITH0) has a Other Operating Expense of €-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Other Operating Expense too high?
Nektar Therapeutics' current Other Operating Expense is €-0.00 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Other Operating Expense compare to OCUL and PVLA?
Nektar Therapeutics' Other Operating Expense of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Other Operating Expense is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.09, compared to a current price of €58.54 — trading 1050.1% above its estimated fair value. The current Other Operating Expense is €-0.00 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Other Operating Expense is €-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €58.54 is trading 1050.1% above its estimated GF Value™ of €5.09. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Other Operating Expense: €-0.00 Mil
  • GF Value™: €5.09 vs. price of €58.54 (1050.1% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for FRA:ITH0

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.54
Price
€5.09
GF Value